Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-BH-A1FE-06A-11R-A213-07

— · A

caa75d1d-281f-5f39-83e0-6dc58fd45344

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A
overall_survival_months
76

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
  • TNFA_SIGNALING_VIA_NFKB+0.500
  • CHOLESTEROL_HOMEOSTASIS+0.440
  • UV_RESPONSE_DN+0.420
  • ANGIOGENESIS+0.390
  • TGF_BETA_SIGNALING+0.370
  • MYOGENESIS+0.360
  • XENOBIOTIC_METABOLISM+0.350
  • COAGULATION+0.340
  • COMPLEMENT+0.320

Top 10 suppressed

  • E2F_TARGETS-0.600
  • G2M_CHECKPOINT-0.500
  • MYC_TARGETS_V1-0.460
  • MYC_TARGETS_V2-0.380
  • DNA_REPAIR-0.350
  • INTERFERON_ALPHA_RESPONSE-0.260
  • ESTROGEN_RESPONSE_LATE-0.240
  • UNFOLDED_PROTEIN_RESPONSE-0.240
  • PI3K_AKT_MTOR_SIGNALING-0.220
  • ESTROGEN_RESPONSE_EARLY-0.190

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MBCproject_0031_T1_RNA
breast-umap@18
—A0.878
2MBCProject_3216_T1_RNA
breast-umap@18
—A0.878
3MBCProject_0419_T2_RNA
breast-umap@18
—A0.875
4SRR8613813
breast-umap@18
—D0.872
5TCGA-BH-A0DV-01A-21R-A12P-07
breast-umap@18
—A0.871
6TCGA-BH-A0DX-01A-11R-A115-07
breast-umap@18
—A0.869
7C3N-00738
lung-landscapes@6
—cohortMD20.863
8SRR8518203
breast-umap@18
—A0.862
9SRR8518186
breast-umap@18
—A0.862
10BSR_14_0175_A4_S56
breast-umap@18
—A0.862

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 33 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.510Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.500Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.440Remibrutinib— uncovered
UV_RESPONSE_DN0.420Inavolisib— uncovered
ANGIOGENESIS0.390Remibrutinib— uncovered
TGF_BETA_SIGNALING0.370Inavolisib— uncovered
MYOGENESIS0.360Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.350Inavolisib— uncovered
COAGULATION0.340Binimetinib— uncovered
COMPLEMENT0.320Inavolisib— uncovered
FATTY_ACID_METABOLISM0.320Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.310Inavolisib— uncovered
APICAL_JUNCTION0.290Inavolisib— uncovered
HYPOXIA0.290Idelalisib— uncovered
ADIPOGENESIS0.280Inavolisib— uncovered
BILE_ACID_METABOLISM0.280Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.260Idelalisib— uncovered
HEDGEHOG_SIGNALING0.240Inavolisib— uncovered
KRAS_SIGNALING_UP0.230Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.210Inavolisib— uncovered